With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and…

Read More

Behavior Changes Happen Outside the Exam Room, But Validation of Lifestyle Medicine Programs Cannot

If CMS and private payers are serious about whole-person health, reimbursement structures must align with the workforce actually delivering that care. Payment pathways should recognize the value of the broader care team and enable the seamless integration of their expertise with the objective data generated through connected devices and programs like RPM. The post Behavior…

Read More